Clinical Trials Browser

Phase 1/2 × pirfenidone × 1 year × Clear all

NCT04467723 2026-01-28

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms